WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130154
CAS#: N/A
Description: THTMP is a potential anticancer agent for the treatment of glioblastoma, increasing glioblastoma cell death. THTMP was found to induce cell death/anti-proliferative activity, through affecting cell cycle arrest and intrinsic apoptosis signaling.
Hodoodo Cat#: H130154
Name: THTMP
CAS#: N/A
Chemical Formula: C23H23NO
Exact Mass: 329.18
Molecular Weight: 329.440
Elemental Analysis: C, 83.85; H, 7.04; N, 4.25; O, 4.86
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: THTMP
IUPAC/Chemical Name: 2-((3,4-dihydroquinolin-1(2H)-yl)(p-tolyl)methyl)phenol
InChi Key: JEVBIIVNLBNALY-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H23NO/c1-17-12-14-19(15-13-17)23(20-9-3-5-11-22(20)25)24-16-6-8-18-7-2-4-10-21(18)24/h2-5,7,9-15,23,25H,6,8,16H2,1H3
SMILES Code: OC1=CC=CC=C1C(N2CCCC3=C2C=CC=C3)C4=CC=C(C)C=C4
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 329.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1. Doan P, Musa A, Candeias NR, Emmert-Streib F, Yli-Harja O, Kandhavelu M. Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway. Front Pharmacol. 2019 Apr 2;10:330. doi: 10.3389/fphar.2019.00330. PMID: 31001122; PMCID: PMC6454069.
2. Doan P, Nguyen P, Murugesan A, Candeias NR, Yli-Harja O, Kandhavelu M. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity. Cells. 2021 Aug 3;10(8):1975. doi: 10.3390/cells10081975. PMID: 34440745; PMCID: PMC8393831.
3. Palanivel S, Yli-Harja O, Kandhavelu M. Molecular interaction study of novel indoline derivatives with EGFR-kinase domain using multiple computational analysis. J Biomol Struct Dyn. 2022 Oct;40(16):7545-7554. doi: 10.1080/07391102.2021.1900917. Epub 2021 Mar 22. PMID: 33749517.
4. Doan P, Musa A, Murugesan A, Sipilä V, Candeias NR, Emmert-Streib F, Ruusuvuori P, Granberg K, Yli-Harja O, Kandhavelu M. Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Cells. 2020 Mar 10;9(3):681. doi: 10.3390/cells9030681. PMID: 32164385; PMCID: PMC7140667.
5. Palanivel S, Yli-Harja O, Kandhavelu M. Alkylamino Phenol Derivative Induces Apoptosis by Inhibiting EGFR Signaling Pathway in Breast Cancer Cells. Anticancer Agents Med Chem. 2020;20(7):809-819. doi: 10.2174/1871520620666200213101407. PMID: 32053080.
